Immuneering Corporation (IMRX)
Immuneering has a market cap or net worth of $267.80 million. The enterprise value is $167.11 million.
The next earnings date is Tuesday, May 9, 2023, before market open.
|Estimated Earnings Date||May 9, 2023|
Immuneering has 26.44 million shares outstanding. The number of shares has increased by 93.84% in one year.
|Shares Change (YoY)||+93.84%|
|Shares Change (QoQ)||+0.05%|
|Owned by Insiders (%)||30.53%|
|Owned by Institutions (%)||44.81%|
|EV / Earnings||n/a|
|EV / Sales||527.25|
|EV / EBITDA||n/a|
|EV / EBIT||n/a|
|EV / FCF||n/a|
The company has a current ratio of 13.50, with a Debt / Equity ratio of 0.04.
|Debt / Equity||0.04|
|Debt / EBITDA||n/a|
|Debt / FCF||n/a|
Return on equity (ROE) is -39.70% and return on invested capital (ROIC) is -97.70%.
|Return on Equity (ROE)||-39.70%|
|Return on Assets (ROA)||-36.70%|
|Return on Capital (ROIC)||-97.70%|
|Revenue Per Employee||$4,283|
|Profits Per Employee||-$682,616|
|Effective Tax Rate||n/a|
Stock Price Statistics
The stock price has increased by +30.77% in the last 52 weeks.
|52-Week Price Change||+30.77%|
|50-Day Moving Average||5.48|
|200-Day Moving Average||7.25|
|Average Volume (30 Days)||43,618|
Short Selling Information
The latest short interest is 863,461, so 3.27% of the outstanding shares have been sold short.
|Short Previous Month||829,271|
|Short % of Shares Out||3.27%|
|Short % of Float||6.20%|
|Short Ratio (days to cover)||21.86|
In the last 12 months, Immuneering had revenue of $316,952 and -$50.51 million in losses. Loss per share was -$1.91.
|Loss Per Share||-$1.91|
The company has $105.52 million in cash and $4.84 million in debt, giving a net cash position of $100.68 million or $3.81 per share.
|Cash & Cash Equivalents||105.52M|
|Net Cash Per Share||$3.81|
|Equity / Book Value||109.85M|
|Book Value Per Share||4.16|
In the last 12 months, operating cash flow was -$44.10 million and capital expenditures -$742,483, giving a free cash flow of -$44.84 million.
|Operating Cash Flow||-44.10M|
|Free Cash Flow||-44.84M|
|FCF Per Share||-$1.70|
Gross margin is 50.11%, with operating and profit margins of -16,325.77% and -15,937.29%.
Dividends & Yields
Immuneering does not appear to pay any dividends at this time.
|Dividend Per Share||n/a|
|Dividend Growth (YoY)||n/a|
The average price target for Immuneering is $16.32, which is 61.11% higher than the current price. The consensus rating is "Buy".
|Price Target Difference||61.11%|
|Revenue Growth Forecast (5Y)||260.76%|
|EPS Growth Forecast (5Y)||-20.23%|
This stock does not have any record of stock splits.
|Last Split Date||n/a|